Abbildung 8: Intervalle
EVIDENCE study design: pre-study MRI scan and clinical assessment; 2 relapses prior 2 years; randomize at SD1; monthly MRI gadolinium assessments until week 24; 3-monthly neurological examinations monthly AE/clinical assessment at time of MRI; monthly phone check between MRI dates to increase relapse ascertainment and reduce number of historical relapses reduced frequency of MRI scans after week 24; primary endpoint at week 24. Second phase from week 24-48; Post-48 week is variable because patients enrolled early continue on therapy until last patient enrolled completes week 48. Transition (T) is when patients switch from Avonex to Rebif.